EPHA2 and glioblastoma: The novel EphA2 inhibitor candidate 4a based on dasatinib was shown to feature an ameliorated selectivity profile while maintaining potent inhibitory effects against EphA2 as well as cytotoxic properties in glioblastoma cells [69].